A federal judge allowed most of a whistleblower suit accusing Harvard and a leading researcher of misusing $275M in NIH grants to proceed, keeping two False Claims Act counts alive.

Remix Therapeutics has agreed to a reverse merger with Passage Bio and lined up an oversubscribed $100M private placement to fund REM‑422 into pivotal readouts.

Thousands of Xfinity customers reported service interruptions Monday; outage trackers logged a sharp spike while engineers worked to restore service.

The FDA says ZOLL Medical’s Chelmsford facility failed to meet device quality and reporting rules. The company has fifteen business days to outline fixes or face enforcement.

Nano Dimension signed a non‑binding term sheet to merge with Infinite Epigenetics in a proposed $890M stock deal that would pivot the Waltham company into AI‑powered health diagnostics. The combined firm would seek the Nasdaq ticker IEAI and access to more than $400M in cash at closing.

Phase II results from Boston suggest the century‑old BCG TB vaccine can lower insulin needs for some people with type 1 diabetes. Early data are promising but experts say larger trials are required.

The Yawkey Foundation pledged $50M to Dana‑Farber to support construction of a new inpatient cancer hospital and related patient care programs in Boston.

Scott Strazik’s Cambridge HQ bet is turning into interns, hires and research money as data‑center demand lifts GE Vernova.

Cambridge's City Therapeutics raised $99.5M in a Series B to accelerate its RNAi pipeline toward human testing and expand Kendall Square labs.

An MIT‑linked effort called Mice Against Ticks would release immune mice on Nantucket to interrupt the Lyme cycle. Lab results push the idea forward even as residents weigh ecological risks.

Mitsubishi Electric has opened Serendie Street Boston in Kendall Square to pilot AI and software projects and tie local research to global R&D.

Eli Lilly has partnered with Boston’s Ascidian to develop RNA exon‑editing therapies for inherited kidney diseases in a deal that could be worth up to $1.9 billion. The collaboration pairs Ascidian’s platform with Lilly’s Seaport genetic‑medicine hub.

NSF is removing instruments from the Ocean Observatories Initiative, ending key below‑surface measurements off the Pacific Northwest as El Niño approaches.